Radium Capital unleashes $400m war chest for Aussie innovators
Posted: 13 June 2025 Radium Capital, Australia’s leader in R&D finance, has announced plans to lend $400 million to Australian innovators over the next 12 months. Radium Capital has deployed more than $900 million to companies undertaking research…
Telix Pharmaceuticals launches new Prostate Cancer Imaging Agent in U.S.
Posted: 13 June 2025 Telix Pharmaceuticals Limited announced that its next-generation PSMA-PET imaging agent for prostate cancer, Gozellix® (kit for the preparation of gallium-68 (68Ga) gozetotide injection), had become commercially available nationwide in the United States (U.S.). Kevin…
Chimeric Therapeutics Receives $2.5 Million Advance on FY25 R&D Tax Incentive
Posted: 12 June 2025 Chimeric Therapeutics Limited (ASX:CHM), an Australian leader in cell therapy, announced the receipt of $2,500,000 from Endpoints Capital under a funding facility secured against the anticipated FY25 Research and Development Tax Incentive (RDTI). The…
Akaal Pharma Pty Ltd Announces Positive Phase-2 Results for Treatment of Atopic Dermatitis and Associated Pruritus
Posted: 11 June 2025 Positive top-line results from a Phase 2 clinical trial were announced by Akaal Pharma Pty Ltd (Akaal Pharma), a biopharmaceutical company focused on novel therapies for inflammatory and autoimmune skin disorders. The multicenter, randomized,…
Peter MacCallum Cancer Centre Announces Promising Prostate Cancer Therapy Results
Posted: 11 June 2025 Peter MacCallum Cancer Centre revealed highly encouraging initial results from its groundbreaking Terbium-161 prostate cancer therapy. The findings were presented at the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting in Chicago and…
Chimeric Therapeutics’ CHM CDH17 Granted FDA Fast Track Designation
Posted: 10 June 2025 Chimeric Therapeutics (ASX:CHM) announced that the US Food and Drug Administration (FDA) had granted Fast Track Designation to CHM CDH17. This designation was based on the FDA’s assessment of CHM CDH17’s potential to improve…
NRFC Invests $27 Million in PolyActiva to Combat Glaucoma
Posted: 10 June 2025 The National Reconstruction Fund Corporation (NRFC) committed $27 million to PolyActiva as part of its $40 million Series C round. PolyActiva, a Melbourne-based biotechnology company, was developing a potentially revolutionary eye implant technology to…
Navigating the complexity of biologics and radiopharmaceuticals
Posted: 6 June 2025 This article summarises key insights from BioMelbourne Network’s BioForum, which brought together experts and participants to explore innovation, potential and challenges in complex biologics and radiopharmaceuticals. With around 90 participants in person and almost…
La Trobe University unveils AI Supercomputer for medical innovation
Posted: 4 June 2025 La Trobe University has “switched on” Australia’s first AI-powered medical innovation centre with NVIDIA DGX H200 systems. This has marked a major step in AI-driven medical and biotech research. Vice-Chancellor Professor Theo Farrell said,…
INOVIQ announces early ovarian cancer screening breakthrough
Posted: 4 June 2025 INOVIQ Limited announced groundbreaking results from its EXO-OC™ ovarian cancer test at the American Society of Clinical Oncology (ASCO) Annual Meeting on June 1, 2025, in Chicago. The test achieved 77% sensitivity and 99.6%…
Senior/Principal Biostatistician
Posted: 4 June 2025 The Company: PureCDM is dedicated to providing a full range of expert biostatistical support to clients in the pharmaceutical, biotechnology, and MedTech industries. Our mission is to break down the complexities of data,…
Noxopharm receives green light for HERACLES clinical trial
Posted: 2 June 2025 BioMelbourne Network is pleased to share that one of our valued members, Noxopharm Limited (ASX:NOX), has received approval from the Human Research Ethics Committee for the HERACLES clinical trial. This approval follows a straightforward…
